To elucidate the role of c-Met signaling and its involvement with HER family signaling as a cancer co-driver, a new test was developed based on the principle of tumor cell impedance alterations from hypersignaling as described previously for patients that we demonstrated do not have overexpressed receptors. Here, MET is linked to cancer.